“Dupilumab appears promising as a steroid-sparing treatment of ADC-induced cutaneous toxicities,” which “are difficult to ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Patients with AD treated with JAK inhibitors show higher risks for PE and deep vein thrombosis than those treated with dupilumab or methotrexate, according to the results of a global cohort study.

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Key Takeaways A new evidence review highlights the best treatments for hivesInjectable antibody drugs omalizumab and dupilumab and an experimental pill called remibrutinib were the most effectiveA ...

Jaina Patel was in her early 30s when a bout of bronchitis led to her losing weight, her job, and eventually her sense of ...

Dupilumab is an IL-4 receptor α antagonist, blocking the signaling of pro-inflammatory cytokines implicated in atopic and allergic diseases, such as asthma, atopic dermatitis, and sinusitis with ...